CVS Health Earnings Call Transcripts
Fiscal Year 2026
-
The meeting approved all management proposals, including director elections and executive compensation, while a shareholder proposal to lower the written consent threshold was rejected. Strong financial results and ongoing strategic initiatives in technology, affordability, and healthcare delivery were highlighted.
-
Q1 2026 saw strong revenue and earnings growth, with adjusted EPS up 14% and full-year guidance raised. Segment performance was robust, especially in Health Care Benefits and value-based care, while investments in technology and regulatory adaptation remain key priorities.
-
Leadership is integrating pharmacy, PBM, and care delivery to create a seamless consumer experience, leveraging technology, acquisitions, and new reimbursement models. Regulatory changes are being proactively addressed, while digital transformation through Health100 aims to enhance engagement and affordability.
Fiscal Year 2025
-
Full year 2025 revenue exceeded $400 billion with strong EPS and cash flow, driven by robust performance across all segments and successful integration of Rite Aid assets. 2026 guidance is reaffirmed, with continued focus on margin recovery, operational excellence, and technology investment.
-
Management outlined a multi-year transformation, delivering strong 2025 results and setting a mid-teens EPS CAGR target through 2028. Key initiatives include a $20B technology investment, launch of an Open Engagement Platform, and margin recovery across all business segments, with upside potential from new technology commercialization.
-
Q3 saw record revenue and strong EPS growth, prompting a raised full-year outlook. All segments contributed, with notable gains in pharmacy and consumer wellness, but a $5.7B goodwill impairment was recorded in healthcare delivery. 2026 guidance anticipates mid-teens EPS growth.
-
Q2 2025 saw revenues rise 8% to nearly $99B, with adjusted EPS of $1.81 and strong Aetna and Pharmacy results offsetting Oak Street pressures. Full-year EPS guidance was raised to $6.30–$6.40, and the CostVantage model transition and $20B healthcare transformation commitment were highlighted.
-
Q1 2025 saw strong revenue and earnings growth, with all segments contributing and full-year EPS guidance raised. The company is exiting the ACA exchange business, expanding access to Wegovy, and maintaining a cautious outlook amid cost and regulatory pressures.
Fiscal Year 2024
-
Q4 2024 saw revenue growth and strong pharmacy performance, but Health Care Benefits faced higher medical costs and losses. 2025 guidance anticipates EPS growth, Aetna recovery, and continued investment in pharmacy transformation and transparency.
-
Leadership changes and new board members are driving strategic shifts, including pricing model innovations. Financial performance is stabilizing, with cautious outlooks for 2024 and 2025 amid cost and membership variability. Pharmacy and health services are transitioning to new models for improved transparency and profitability.
-
Third quarter revenue grew 6% to $95.4B, but healthcare benefits posted a loss due to high utilization and PDRs. No formal 2024 guidance was given, but margin recovery is expected in 2025 as benefit and pricing changes take effect.
-
Q2 2024 saw $91.2B in revenue and $1.83 adjusted EPS, with strong pharmacy and health services offsetting healthcare benefits pressure. 2024 EPS guidance was lowered, but 2025 margin recovery and productivity initiatives are expected to drive improvement.